Osimertinib combined bevacizumab in untreated epidermal growth factor receptor mutaeted non-small-cell lung cancer patients with malignant pleural and/or pericardial effusion -phase II trial-
Phase of Trial: Phase II
Latest Information Update: 10 Jan 2019
At a glance
- Drugs Bevacizumab (Primary) ; Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms SPIRAL II Study
- 07 Jan 2019 Planned number of patients changed from 36 to 30.
- 07 Jan 2019 Planned End Date changed from 31 Aug 2019 to 30 Sep 2021.
- 07 Jan 2019 Status changed from suspended to recruiting.